Brought to you by 
Santhera grants Biovail rights to fipamezole; ends
28 Oct 2010
Executive Summary
Days after acquiring fipamezole (JP1730) by exercising an option to take over the drug candidate's originator Juvantia, Swiss spec pharma Santhera is immediately monetizing the pharmaceutical asset, carving out US and Canadian rights to Biovail. Fipamezole has completed Phase II for levodopa-induced Parkinson's dyskinesia.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Santhera grants Biovail rights to fipamezole; ends
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice